Current society guidance (NCS, ACNS, AHA and allied consensus statements) converges on the
following evidence-based principles: (a) electroencephalography (EEG) is essential for suspected
ongoing SE and for many critically ill patients with depressed or fluctuating consciousness; (b) time
to EEG matters, earlier monitoring increases the probability of detecting electrographic seizures that
would otherwise be missed and guides safer, more precise treatment; (c) monitoring duration should be
individualized but typically extends ≥24 hours after electrographic seizure control; and (d) addressing
implementation barriers (technologist availability, device footprint, remote interpretation, and staff
training) is necessary to translate guideline recommendations into routine clinical practice. BrainView
NeuroTrace’s innovative technology platform uniquely combines high-fidelity EEG acquisition, AIassisted
detection, rapid deployment, and cloud-enabled remote monitoring to fill current gaps in access,
scalability, and workflow efficiency. This comprehensive approach empowers clinicians to deliver
timely, guideline-concordant care across a spectrum of settings, from rural and community hospitals to
ambulatory and post–cardiac arrest care. As such, there is an opportunity to profoundly improve patient
outcomes, and concomitantly contain costs. Urgent adoption of advanced EEG systems like BrainView
NeuroTrace represents a critical step toward transforming SE management and expanding the reach of
neurodiagnostic services beyond single-point competitors.
